After Sanofi leadership telegraphed an upsized appetite for business development last month, signals have emerged that the ...
The FDA has slammed Johnson & Johnson over misleading claims about its bladder cancer drug Inlexzo, accusing the pharma ...
Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the early 2030s, as the ...
Underscoring how crowded the U.S. market for generalized myasthenia gravis (gMG) has become, the FDA on Wednesday approved ...
Lotte Biologics, a South Korea-headquartered CDMO established in 2022, has inked a large manufacturing deal with an unnamed ...
Biogen is visualizing life amid disease progression in its newest Friedreich ataxia (FA)-focused campaign, reminding ...
Abu Dhabi-based Arcera Life Sciences has pledged more than $1 billion in totality for the rights to potentially take ...
Salerno Pharmaceuticals of Tulsa, Oklahoma, is facing pressure from the FDA to yank its lone commercial product. | In a ...
Beren Therapeutics has officially seen a cyclodextrin therapy across the finish line, scoring an FDA approval in Niemann-Pick ...
After delaying the phase 3 readout of its Alzheimer’s psychosis program for Cobenfy earlier this year, Bristol Myers Squibb ...
AI has moved from experimentation to expectation. As tools become widely available, competitive intelligence clients are no longer asking whether providers use AI. | AI is becoming a commodity. Javier ...
AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results